Kroatia - kroatisk - HALMED (Agencija za lijekove i medicinske proizvode)

arenda d.o.o. medarska ulica 56/b 10000 zagreb -

Den europeiske union - kroatisk - EMA (European Medicines Agency)

advanced accelerator applications - lutetijev (177lu) oksodotreotid - neuroendokrinim tumorima - ostali terapeutski radiofarmaceutici - lutathera je indiciran u liječenju inoperabilnim ili metastatskim, progresivni, dobro diferencirani (g1 i g2), somatostatin receptora pozitivne gastroenteropancreatic neuroendokrinim tumorima (gep‑nets) u odraslih.

Den europeiske union - kroatisk - EMA (European Medicines Agency)

roche registration gmbh - vismodegib - karcinom, bazalna stanica - antineoplastična sredstva - erivedge indiciran za liječenje odraslih bolesnika s simptomatske метастатической базальноклеточной karcinom - местнораспространенного базально srpastih stanica karcinom neprikladne za kirurško liječenje ili radioterapije.

Bosnia-Hercegovina - kroatisk - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

oktal pharma d.o.o. sarajevo - amlodipin, Индапамид, Периндоприл - filmom obložena tableta - 2.5 mg/1 tableta+ 0.625 mg/1 tableta+ 5 mg/1 tableta - jedna filmom obložena tableta sadrži: 2,5 mg perindopril arginina (što odgovara 1,6975 mg perindoprila), 0,625 mg indapamida, 5 mg amlodipina (što odgovara 6,935 mg amlodipin besilata)

Bosnia-Hercegovina - kroatisk - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

oktal pharma d.o.o. sarajevo - amlodipin, Индапамид, Периндоприл - filmom obložena tableta - 5 mg/1 tableta+ 1.25 mg/1 tableta+ 5 mg/1 tableta - jedna filmom obložena tableta sadrži: 5 mg perindopril arginina (što odgovara 3,395 mg perindoprila), 1,25 mg indapamida, 5 mg amlodipina (što odgovara 6,935 mg amlodipin besilata)

Bosnia-Hercegovina - kroatisk - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

oktal pharma d.o.o. sarajevo - amlodipin, Индапамид, Периндоприл - filmom obložena tableta - 5 mg/1 tableta+ 1.25 mg/1 tableta+ 10 mg/1 tableta - jedna filmom obložena tableta sadrži: 5 mg perindopril arginina (što odgovara 3,395 mg perindoprila), 1,25 mg indapamida, 10 mg amlodipina (što odgovara 13,870 mg amlodipin besilata)

Bosnia-Hercegovina - kroatisk - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

oktal pharma d.o.o. sarajevo - amlodipin, Индапамид, Периндоприл - filmom obložena tableta - 10 mg/1 tableta+ 2.5 mg/1 tableta+ 5 mg/1 tableta - jedna filmom obložena tableta sadrži: 10 mg perindopril arginina (što odgovara 6,790 mg perindoprila), 2,5 mg indapamida, 5 mg amlodipina (što odgovara 6,935 mg amlodipin besilata)

Bosnia-Hercegovina - kroatisk - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

oktal pharma d.o.o. sarajevo - amlodipin, Индапамид, Периндоприл - filmom obložena tableta - 10 mg/1 tableta+ 2.5 mg/1 tableta+ 10 mg/1 tableta - jedna filmom obložena tableta sadrži: 10 mg perindopril arginina (što odgovara 6,790 mg perindoprila), 2,5 mg indapamida, 10 mg amlodipina (što odgovara 13,870 mg amlodipin besilata)

Den europeiske union - kroatisk - EMA (European Medicines Agency)

takeda pharma a/s - brigatinib - karcinom, ne-malih stanica pluća - antineoplastična sredstva - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.

Den europeiske union - kroatisk - EMA (European Medicines Agency)

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - antineoplastična sredstva - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq u monoterapiji namijenjen za liječenje odraslih bolesnika s lokalno-uobičajena ili metastatskih НМРЛ nakon što je ranije kemoterapije. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq u monoterapiji namijenjen za liječenje odraslih bolesnika s lokalno-uobičajena ili metastatskih НМРЛ nakon što je ranije kemoterapije. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.